Jamieson Wellness Inc. President and CEO Mark Hornick to Retire

Mike Pilato appointed President and CEO effective June 1, 2021

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX:JWEL) announced today that the Company's President and CEO Mark Hornick has decided to retire, after leading Jamieson Wellness through seven years of unprecedented growth. Jamieson Canada President Mike Pilato will advance to the role of President and CEO, effective June 1, 2021.

"I am thankful to Mark for his skillful leadership building our global presence and entrenching Jamieson as one of Canada's most trusted brands," said David Williams, Chair of the Board of Directors at Jamieson Wellness. "During his tenure, Mark restructured the organization behind a new vision, mission, and values, and with the support of a new leadership team, implemented a rapid growth strategy, doubling the company's topline revenue. The Board of Directors and I wish Mark the very best in his retirement and as we look to the future, we are confident that Mike is the right leader to take Jamieson to the next level."

"It has been my absolute honour to lead this company for the past seven years," said Mr. Hornick. "Our business has never been stronger, supported by a powerful brand, engaging culture and the deep commitment of our employees. The momentum we have driven over the past few years is still building, reinforcing that we have the right strategy in place to meet our long-term objectives. Mike is highly experienced with a proven track record of excellence and shared vision of improving the world's health and wellness. Over the next few months, Mike and I will work together to complete what has been an ongoing leadership transition."

"Jamieson Wellness is a highly respected global company with an amazing, dedicated team and an iconic brand that consumers around the world trust to support their health and wellness needs," said Mr. Pilato. "We have honed the company's long-term strategy over the past two years, prioritizing international growth opportunities, especially in China, along with fueling our organic growth in Canada. I am committed to building on this strategy and ensuring a seamless transition. I thank Mark and the Board of Directors for their support and confidence and look forward to working closely with the entire Jamieson team to continue driving sustainable growth and market leadership expansion."

Mr. Pilato joined Jamieson Wellness in 2018 as President of the Company's Specialty Brands division and was promoted to President, Jamieson Canada, in February 2020. Prior to Jamieson, Mr. Pilato held multiple leadership positions in the CPG space, culminating with serving as General Manager and President of The Clorox Company of Canada. During his tenure he led the organization to four years of record growth across multiple categories including household products, natural health and personal care.

About Jamieson Wellness Inc.

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness manufactures and markets sports nutrition products and specialty supplements under its Progressive, Precision and Iron Vegan brands. The Company also markets Smart Solutions by Lorna Vanderhaeghe, the #1 women's natural health focused brand in Canada. For more information please visit jamiesonwellness.com.

Forward-Looking Information

This press release may contain forward-looking information within the meaning of applicable securities legislation. Such information includes, but is not limited to, statements related to the Company's future plans, goals, strategies, intentions, beliefs, objectives, economic performance or expectations. Words such as "expect", "anticipate", "intend", "may", "will", "estimate" and variations of such words and similar expressions are intended to identify such forward-looking information. This information reflects the Company's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under "Risk Factors" in the Company's Annual Information Form dated March 27, 2020 and under the "Risk Factors" section in the Company's MD&A filed February 25, 2021. This information is based on the Company's reasonable assumptions and beliefs in light of the information currently available to it and the statements are made as of the date of this press release. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law or regulatory authority.

The Company cautions that the list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect the Company's results. Readers are urged to consider the risks, uncertainties and assumptions associated with these statements carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. See "Forward-looking Information" and "Risk Factors" within the Company's MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements.

Investor and Media Contact:  
Ruth Winker
Jamieson Wellness
416-705-5437
rwinker@jamiesonlabs.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Invion Limited

Invion Limited

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial

Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients
with acute myocarditis, with topline data expected in Q2 2025

Keep reading...Show less

Latest Press Releases

Related News

×